A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Solventum Corporation ("Solventum," "we," "our," "us," or the "Company"), is a leading global healthcare company developing, manufacturing, and commercializing a broad portfolio of solutions that leverages deep material science, data science, and digital capabilities to address critical customer and patient needs. We constantly seek to enable the improvement of standards of care and move healthcare forward with innovation powered by insights, clinical intelligence, technology, and manufacturing expertise. Our 70+ year history of discovering and innovating advanced solutions has helped us solve our customers’ toughest challenges. Our solutions are relied on every day within the global healthcare industry to deliver higher-quality patient care, more efficient processes and workflows, and improved standards of safety and accuracy. Additionally, our products and services are present along a patient’s journey through prevention, diagnosis, treatment, and recovery.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 8.3B | 8.3B | 8.3B | 8.2B | 8.1B |
| Net Income | 1.6B | 1.6B | 479M | 1.3B | 1.3B |
| EPS | $8.88 | $8.88 | $2.76 | $7.79 | $7.78 |
| Free Cash Flow | -10M | -10M | 805M | 1.6B | 1.4B |
| ROIC | 21.5% | 22.0% | 8.5% | 12.1% | - |
| Gross Margin | 53.5% | 53.5% | 55.6% | 57.3% | 57.7% |
| Debt/Equity | 1.00 | 1.00 | 2.77 | 0.00 | - |
| Dividends/Share | $0.00 | - | - | - | - |
| Operating Income | 2.2B | 2.2B | 1.0B | 1.7B | 1.7B |
| Operating Margin | 26.2% | 26.2% | 12.6% | 20.6% | 20.8% |
| ROE | 30.8% | 38.9% | 16.2% | 11.5% | - |
| Shares Outstanding | 175M | 175M | 174M | 173M | 173M |
| Metric | 2022 | 2023 | |||
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 8.1B | 8.2B | 8.3B | 8.3B | 8.3B |
| Gross Margin | 57.7% | 57.3% | 55.6% | 53.5% | 53.5% |
| R&D | 767M | 758M | 775M | 739M | 739M |
| SG&A | 2.2B | 2.2B | 2.8B | 3.1B | 3.1B |
| EBIT | 1.7B | 1.7B | 1.0B | 2.2B | 2.2B |
| Op. Margin | 20.8% | 20.6% | 12.6% | 26.2% | 26.2% |
| Net Income | 1.3B | 1.3B | 479M | 1.6B | 1.6B |
| Net Margin | 16.5% | 16.4% | 5.8% | 18.7% | 18.7% |
| Non-Recurring | 0 | 0 | 62M | 1.5B | 1.5B |
| Returns on Capital | |||||
| ROIC | N/A | 12.1% | 8.5% | 22.0% | 21.5% |
| ROE | N/A | 11.5% | 16.2% | 38.9% | 30.8% |
| ROA | N/A | 9.7% | 3.3% | 10.8% | 10.9% |
| Cash Flow | |||||
| Op. Cash Flow | 1.7B | 1.9B | 1.2B | 369M | 369M |
| Free Cash Flow | 1.4B | 1.6B | 805M | -10M | -10M |
| Owner Earnings | 1.1B | 1.3B | 518M | -281M | -281M |
| CapEx | 251M | 290M | 380M | 379M | 379M |
| Maint. CapEx | 578M | 561M | 555M | 489M | 489M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 |
| D&A | 578M | 561M | 555M | 489M | 489M |
| CapEx/OCF | N/A | N/A | 32.1% | 102.7% | 102.7% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 37M | 39M | 112M | 161M | 161M |
| Debt Repayment | 0 | 0 | 300M | 3.1B | 3.1B |
| Balance Sheet | |||||
| Net Debt | N/A | -388M | 6.7B | 3.3B | 4.2B |
| Cash & Equiv. | 61M | 194M | 762M | 878M | 878M |
| Long-Term Debt | N/A | 0 | 7.8B | 5.0B | 5.0B |
| Debt/Equity | N/A | 0.00 | 2.77 | 1.00 | 1.00 |
| Interest Coverage | 434.1 | N/A | 2.8 | 6.3 | 6.3 |
| Equity | N/A | 11.7B | 3.0B | 5.0B | 5.0B |
| Total Assets | N/A | 13.9B | 14.5B | 14.3B | 14.3B |
| Total Liabilities | N/A | 2.3B | 11.5B | 9.2B | 9.2B |
| Intangibles | N/A | 2.9B | 2.5B | 2.6B | 2.6B |
| Retained Earnings | N/A | 0 | 242M | 1.8B | 1.8B |
| Working Capital | N/A | 791M | 546M | 723M | 723M |
| Current Assets | N/A | 2.5B | 3.2B | 3.9B | 3.9B |
| Current Liabilities | N/A | 1.7B | 2.7B | 3.1B | 3.1B |
| Per Share Data | |||||
| EPS | 7.78 | 7.79 | 2.76 | 8.88 | 8.88 |
| Owner EPS | 6.16 | 7.61 | 2.98 | -1.60 | -1.60 |
| Book Value | N/A | 67.52 | 17.05 | 28.81 | 28.81 |
| Cash Flow/Share | 9.73 | 11.08 | 6.83 | 2.11 | 11.67 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 172.6M | 172.8M | 173.6M | 175.2M | 175.2M |
| Valuation | |||||
| P/E Ratio | N/A | N/A | 24.2 | 9.1 | 7.6 |
| P/FCF | N/A | N/A | 14.4 | N/A | N/A |
| EV/EBIT | N/A | N/A | 17.6 | 8.0 | 7.3 |
| Price/Book | N/A | N/A | 3.9 | 2.8 | 2.3 |
| Price/Sales | N/A | N/A | 1.3 | 1.6 | 1.4 |
| FCF Yield | N/A | N/A | 6.9% | -0.1% | -0.1% |
| Market Cap | 0 | N/A | 11.6B | 14.1B | 11.8B |
| Avg. Price | 0.00 | N/A | 63.78 | 73.67 | 67.41 |
| Year-End Price | 0.00 | N/A | 66.74 | 80.46 | 67.41 |
Solventum Corp passes 4 of 9 quality checks, suggesting mixed fundamentals.
Solventum Corp trades at 7.6x trailing earnings, compared to its 15-year median P/E of 16.6x, suggesting it is currently Cheap relative to its historical range. The company's 5-year average ROIC is 14.2% with a gross margin of 56.0%. At current prices, the estimated annualized return to fair value is -56.0%.
Solventum Corp (SOLV) has a current P/E ratio of 7.6, compared to its historical median P/E of 16.6. The stock is currently considered Cheap based on its historical valuation range.
Solventum Corp (SOLV) has a 5-year average return on invested capital (ROIC) of 14.2%. This indicates solid capital allocation.
Solventum Corp (SOLV) has a market capitalization of $11.8B. It is classified as a large-cap stock.
Solventum Corp (SOLV) does not currently pay a regular dividend.
Based on historical P/E analysis, Solventum Corp (SOLV) appears cheap. The current P/E of 7.6 is 54% below its historical median of 16.6. The estimated fair value CAGR (P/E method) is -6.0%.
Solventum Corp (SOLV) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
Solventum Corp (SOLV) reported annual revenue of $8.3 billion in its most recent fiscal year, based on SEC EDGAR filings.
Solventum Corp (SOLV) has a net profit margin of 18.7%. This is a healthy margin.
Solventum Corp (SOLV) generated $-10 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Solventum Corp (SOLV) has a debt-to-equity ratio of 1.00. This indicates moderate leverage.
Solventum Corp (SOLV) reported earnings per share (EPS) of $8.88 in its most recent fiscal year.
Solventum Corp (SOLV) has a return on equity (ROE) of 38.9%. This indicates the company generates strong returns for shareholders.
Solventum Corp (SOLV) has a 5-year average gross margin of 56.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 4 years of financial data for Solventum Corp (SOLV), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Solventum Corp (SOLV) has a book value per share of $28.81, based on its most recent annual SEC filing.